Amgen Will Develop Predix S1P1 Modulators For Autoimmune Diseases
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen will license preclinical S1P1 modulators from Predix for $20 mil. plus additional milestone payments up to $287.5 mil.